Cite
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
MLA
Stark, Dan P., et al. “Quality of Life with Cediranib in Relapsed Ovarian Cancer: The ICON6 Phase 3 Randomized Clinical Trial.” Cancer (0008543X), vol. 123, no. 14, July 2017, pp. 2752–61. EBSCOhost, https://doi.org/10.1002/cncr.30657.
APA
Stark, D. P., Cook, A., Brown, J. M., Brundage, M. D., Embleton, A. C., Kaplan, R. S., Raja, F. A., Swart, A. M. W., Velikova, G., Qian, W., & Ledermann, J. A. (2017). Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. Cancer (0008543X), 123(14), 2752–2761. https://doi.org/10.1002/cncr.30657
Chicago
Stark, Dan P., Adrian Cook, Julia M. Brown, Michael D. Brundage, Andrew C. Embleton, Richard S. Kaplan, Fharat A. Raja, et al. 2017. “Quality of Life with Cediranib in Relapsed Ovarian Cancer: The ICON6 Phase 3 Randomized Clinical Trial.” Cancer (0008543X) 123 (14): 2752–61. doi:10.1002/cncr.30657.